https://www.taxtmi.com/news?id=21682 A bilateral regulatory engagement sought to facilitate Indian pharmaceutical exports to China by addressing market access and procedural barriers. India requested China to open access for affordable generics and remove obstacles such as long approval timelines, unclear registration guidelines, local bio equivalence and clinical trial requirements, and mandatory local batch testing, while seeking recognition for approvals by stringent authorities and adoption of risk based batch testing with self certification. Complementary measures include training, B2B meetings, a Pharmexcil-CCCMPHIE MoU, help desks, and a joint pharmaceuticals working group under the Strategic Economic Dialogue. en-us Fri, 12 Jul 2019 16:31:31 +0530 Fri, 12 Jul 2019 16:31:31 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=21682 A bilateral regulatory engagement sought to facilitate Indian pharmaceutical exports to China by addressing market access and procedural barriers. India requested China to open access for affordable generics and remove obstacles such as long approval timelines, unclear registration guidelines, local bio equivalence and clinical trial requirements, and mandatory local batch testing, while seeking recognition for approvals by stringent authorities and adoption of risk based batch testing with self certification. Complementary measures include training, B2B meetings, a Pharmexcil-CCCMPHIE MoU, help desks, and a joint pharmaceuticals working group under the Strategic Economic Dialogue. News - Fri, 12 Jul 2019 16:31:31 +0530 https://www.taxtmi.com/news?id=21682